Elora Pliska, NP
Family · Bellevue, WANPI 1609316371
Payments from drug & device makers
Across 80 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$268
- Lilly USA, LLC$235
- Novo Nordisk$161
- AbbVie$144
- Johnson & Johnson$96
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$77
- plus $447 from 15 others
What the payments were for
- Food & beverage$1,421100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 16 | $268 |
| Lilly USA, LLC | 15 | $235 |
| Novo Nordisk | 9 | $161 |
| AbbVie | 8 | $144 |
| Johnson & Johnson | 5 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $77 |
| AstraZeneca | 1 | $71 |
| Pfizer | 3 | $51 |
| Novartis | 2 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Bayer | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Boehringer Ingelheim | 1 | $26 |
| VBI Vaccine (delaware) Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Corium, LLC | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$1,427 in reported general payments places this provider in the 85th percentile of 1,706 family providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $131 |
| Methylprednisolone | 11 | $81 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $80 |
| Azithromycin | 13 | $43 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $37 |
Paid to pharmacies, not to this prescriber.
Other family in Bellevue
- Hye-Jin GehringBellevue$30K
- Patric SchineCentralia$842K
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
- Kaitlin BrasierSeattle$29K
- Karen JohnsonSeattle$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.